Obesity pharmacotherapy: Current perspectives and future directions

Current Cardiology Reviews

Volumn 9, Issue 1, 2013, Pages 33-54

  Misra, Monika ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Drug targets; Obesity; Pharmacotherapy

Indexed keywords

2,4 DINITROPHENOL; AMFEBUTAMONE PLUS ZONISAMIDE; AMINOREX; ANTIOBESITY AGENT; CETILISTAT; CHOLECYSTOKININ; ENTEROSTATIN; GHRELIN; GLUCAGON LIKE PEPTIDE 1; HISTAMINE H3 RECEPTOR ANTAGONIST; INSULIN; LEPTIN; LEPTIN RECEPTOR; LIRAGLUTIDE; LORCASERIN; MELANOCORTIN RECEPTOR AGONIST; NEUROPEPTIDE Y; OAP 189; OBINEPITIDE; OREXIN A; OREXIN B; PANCREAS POLYPEPTIDE; PEPTIDE YY; PROOPIOMELANOCORTIN; PROTIRELIN; RIMONABANT; SIBUTRAMINE; TESOFENSINE; TETRAHYDROLIPSTATIN; THYROID HORMONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; ADIPOCYTE; AGRANULOCYTOSIS; BODY WEIGHT; BRAIN STEM RESPONSE; BROWN ADIPOSE TISSUE; CALORIC INTAKE; CALORIC RESTRICTION; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; CONSTIPATION; DEPRESSION; DERMATITIS; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG RECALL; DRUG TOLERABILITY; DYSPEPSIA; ENERGY BALANCE; ENERGY EXPENDITURE; FEEDING BEHAVIOR; FLATULENCE; FOOD AND DRUG ADMINISTRATION; HARD FECES; HEART ARRHYTHMIA; HOMEOSTASIS; HUMAN; HYPERTENSION; HYPERTHYROIDISM; HYPOTHALAMUS; INSOMNIA; LATERAL HYPOTHALAMUS; LIFESTYLE MODIFICATION; LIPID DIET; LIPID STORAGE; NAUSEA; NERVE CELL; NEUROENDOCRINE SYSTEM; NEUROPATHY; OBESITY; OFF LABEL DRUG USE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; PULMONARY HYPERTENSION; REVIEW; SATIETY; SENSORY NERVE; SIGNAL TRANSDUCTION; SOLITARY TRACT NUCLEUS; SUICIDAL IDEATION; VISUAL IMPAIRMENT; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION; WHITE ADIPOSE TISSUE; XEROSTOMIA; ZONA INCERTA;

EID: 84875843292     PISSN: 1573403X     EISSN: 18756557     Source Type: Journal    
DOI: 10.2174/1573403x11309010006     Document Type: Review

References (249)

1. World Health Organization. Unhealthy diets and physical inactivity. The problem. Available from: http://www.who.int/nmh/publications/fact sheet_diet_en.pdf. Accessed on September 9, 2011
2. Allison DB, Fontaine KR, Manson JE, Stevens J, VanItallie TB. Annual deaths attributable to obesity in the United States. JAMA 1999;282(16):1530-8.
3. National Institutes of Health, National Heart, Lung, and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obes Res 1998;6(suppl 2):S51-S210.
4. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010;303(3):235-41.
5. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake and body weight. Nature 2006;443(7109):289-95.
6. Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004; 116:337-350
7. Cumming DE, Overduin J. Gastrointestinal regulation of food intake. J Clin Invest 2007;117(1): 13-23.
8. Chiesi M, Huppertz C, Hofbauer KG. Pharmacotherapy of obesity: targets and perspectives. Trends Pharmacol Sci 2001;22(5):247-54.
9. Field BC, Chaudhri OB, Bloom SR. Obesity treatment: novel peripheral targets. Br J Clin Pharmacol 2009;68(6):830-43.
10. Clapham JC, Arch JR, Tadayyon M. Anti-obesity drugs: a critical review of current therapies and future opportunities. Pharmacol Ther 2001;89(1):81-121
11. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372(6505):425-32
12. Dallongeville J, Fruchart JC, Auwerx J. Leptin, a pleiotropic hormone: physiology, pharmacology, and strategies for discovery of leptin modulators. J Med Chem 1998;41(27):5337-52
13. Frühbeck G. Intracellular signalling pathways activated by leptin. Biochem J 2006;393(Pt 1):7-20
14. Heymsfield SB, Greenberg AS, Fujioka K, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999;282(16):1568-75.
15. Foster-Schubert KE, Cummings DE. Emerging therapeutic strategies for obesity. Endocr Rev 2006;27(7):779-93.
16. Veniant MM, LeBel CP. Leptin: from animals to humans. Curr Pharm Des 2003;9(10):811-8.
17. Morris DL, Rui L. Recent advances in understanding leptin signaling and leptin resistance. Am J Physio Endocrinol Metab 2009;297(6):E1247-59.
18. El-Haschimi K, Pierroz DD, Hileman SM, Bjørbaek C, Flier JS. Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity. J Clin Invest 2000;105(12):1827-32.
19. Hofbauer KG, Nicholson JR, Boss O. The obesity epidemic: current and future pharmacological treatments. Annu Rev Pharmacol Toxicol 2007; 47: 565-92.
20. Weigle DS. Pharmacological therapy of obesity: past, present, and future. Clin Endocrinol Metab 2003; 88(6): 2462-9.
21. Ioannides-Demos LL, Piccenna L, McNeil JJ. Pharmacotherapies for obesity: past, current, and future therapies. J Obes 2011; 1-18.
22. Bhasin S, Wallace W, Lawrence JB, Lesch M. Sudden death associated with thyroid hormone abuse. Am J Med 1981; 71(5): 887-90.
23. Gurtner HP. Aminorex and pulmonary hypertension. A review. Cor Vasa 1985; 27(2-3): 160-71.
24. Holden C. Amphetamines: tighter controls on the horizon. Science 1976; 194(4269): 1027-8.
25. Pi-Sunyer FX. Heart valve lesions in patients treated with appetite suppressants. Obes Res 1999; 7(4): 414-6.
26. Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000; 343(25): 1826-32.
27. Li MF, Cheung BM. Rise and fall of anti-obesity drugs. World J Diabetes 2011; 2(2): 19-23.
28. McNeely W, Goa KL. Sibutramine. A review of its contribution to the management of obesity. Drugs 1998; 56(6): 1093-124.
29. James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363(10):905-17
30. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med. 2002;346(8):591-602.
31. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 2007;369(9555):71-7.
32. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord. 1997;21(Suppl 3):S12-23.
33. Li M, Cheung BM. Pharmacotherapy for obesity. Br J Clin Pharmacol. 2009;68(6):804-10
34. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142(7):532-46.
35. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27(1): 155-61.
36. Schneider R, Golzman B, Turkot S, Kogan J, Oren S. Effect of weight loss on blood pressure, arterial compliance, and insulin resistance in normotensive obese subjects. Am J Med Sci 2005; 330(4): 157-60.
37. Beck-da-Silva L, Higginson L, Fraser M, Williams K, Haddad H. Effect of Orlistat in obese patients with heart failure: a pilot study. Congest Heart Fail 2005; 11(3): 118-23.
38. Snow V, Barry P, Fitterman N, Qaseem A, Weiss K. Efficacy Assessment Subcommittee of the American College of Physicians. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2005; 142(7): 525-31.
39. Boozer CN, Leibel RL, Love RJ, Cha MC, Aronne LJ. Synergy of sibutramine and low-dose leptin in treatment of diet-induced obesity in rats. Metabolism 2001; 50(8): 889-93.
40. Rosenbaum M, Goldsmith R, Bloomfield D et al. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J Clin Invest 2005; 115(12): 3579-86.
41. MacLean PS, Higgins JA, Johnson GC, et al. Enhanced metabolic efficiency contributes to weight regain after weight loss in obesityprone rats. Am J Physiol Regul Integr Comp Physiol 2004; 287(6): R1306-15.
42. Breslow MJ, Min-Lee K, Brown DR, Chacko VP, Palmer D, Berkowitz DE. Effect of leptin deficiency on metabolic rate in ob/ob mice. Am J Physiol 1999; 276(3 Pt 1): E443-9.
43. Farooqi IS, Matarese G, Lord GM, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002; 110(8): 1093-103.
44. Rosenbaum M, Murphy EM, Heymsfield SB, Matthews DE, Leibel RL. Low dose leptin administration reverses effects of sustained weight-reduction on energy expenditure and circulating concentrations of thyroid hormones. J Clin Endocrinol Metab 2002; 87(5): 2391-4.
45. Novakovic ZM, Leinung MC, Lee DW, Grasso P. Intranasal administration of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, enhances total uptake and bioavailability in Swiss Webster mice when compared to intraperitoneal, subcutaneous, and intramuscular delivery systems. Regul Pept 2009; 154(1-3): 107-11.
46. Otvos L Jr, Terrasi M, Cascio S, et al. Development of a pharmacologically improved peptide agonist of the leptin receptor. Biochem Biophys Acta 2008; 1783(10): 1745-54.
47. Roth JD, Roland BL, Cole RL, et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl AcadSci USA 2008; 105(20): 7257-62.
48. Talbert ME, Langefeld CD, Ziegler J, et al. Polymorphisms near SOCS3 are associated with obesity and glucose homeostasis traits in Hispanic Americans from the Insulin Resistance Atherosclerosis Family Study. Hum Genet 2009; 125(2): 153-62.
49. Cheyssac C, Lecoeur C, Dechaume A, et al. Analysis of common PTPN1 gene variants in type 2 diabetes, obesity and associated phenotypes in the French population. BMC Med Genet 2006; 7: 44-54.
50. Howard JK, Cave BJ, Oksanen LJ, Tzameli I, Bjørbaek C, Flier JS. Enhanced leptin sensitivity and attenuation of diet-induced obesity in mice with haploinsufficiency of SOCS3. Nat Med 2004; 10(7): 734-8.
51. Zhang ZY, Lee SY. PTP1B inhibitors as potential therapeutics in the treatment of type 2 diabetes and obesity. Expert Opin Investig Drugs 2003; 12(2): 223-33.
52. Lantz KA, Hart SG, Planey SL, et al. Inhibition of PTP1B by Trodusquemine (MSI-1436) Causes Fat-specific Weight Loss in Dietinduced Obese Mice. Obesity (Silver Spring) 2010; 18(8): 1516-23.
53. Coll AP, Loraine Tung YC. Pro-opiomelanocortin (POMC)-derived peptides and the regulation of energy homeostasis. Mol Cell Endocrinol 2009; 300(1-2): 147-51.
54. Barb CR, Robertson AS, Barrett JB, Kraeling RR, Houseknecht KL. The role of melanocortin-3 and-4 receptor in regulating appetite, energy homeostasis and neuroendocrine function in the pig. J Endocrinol 2004; 181(1): 39-52.
55. Masuzaki H, Tanaka T, Ebihara K, Hosoda K, NakaoK. Energy homeostasis regulated by an adipocyte-derived hormone-mechanism of leptin resistance and role of hypothalamic melanocortin signaling. Nippon Rinsho 2009; 67(2): 287-96.
56. Huszar D, Lynch CA, Fairchild-Huntress V, et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997; 88(1): 131-41.
57. Vaisse C, Clement K, Durand E, Hercberg S, Guy-Grand B, Froguel P. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Invest 2000; 106(2): 253-62.
58. Ni XP, Butler AA, Cone RD, Humphreys MH. Central receptors mediating the cardiovascular actions of melanocyte stimulating hormones. J Hypertens 2006; 24(11): 2239-46.
59. Giuliano F. Control of penile erection by the melanocortinergic system: experimental evidences and therapeutic perspectives. J Androl 2004; 25(5): 683-91.
60. Deboer MD, Marks DL. Cachexia: lessons from melanocortin antagonism. Trends EndocrinolMetab 2006; 17(5): 199-204.
61. Lee M, Wardlaw SL. The central melanocortin system and the regulation of energy balance. Front Biosci 2007; 12: 3994-4010.
62. Ye Z, Guo L, Barakat KJ, et al. Discovery and activity of (1R,4S,6R)-N-[(1R)-2-[4-cyclohexyl-4-[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-methyl-2-azabicyclo[2.2.2]octane-6-carboxamide (3, RY764), a potent and selective melanocortin subtype-4 receptor agonist. Bioorg Med Chem Lett 2005; 15(15): 3501-5.
63. Krishna R, Gumbiner B, Stevens C, et al. Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy. Clin Pharmacol Ther 2009; 86(6): 659-66.
64. Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res 2004; 16(1): 51-9.
65. Wisse BE, Frayo RS, Schwartz MW, Cummings DE. Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology 2001; 142(8): 3292-301.
66. Vos TJ, Caracoti A, Che JL, et al. Identification of 2-[2-[2-(5-bromo-2-methoxyphenyl)-ethyl]-3-fluorophenyl]-4,5-dihydro-1Himidazole (ML00253764), a small molecule melanocortin 4 receptor antagonist that effectively reduces tumor-induced weight loss in a mouse model. J Med Chem 2004; 47(7): 1602-4.
67. Baskin DG. Single-minded view of melanocortin signaling in energy homeostasis. Endocrinology 2006; 147(10): 4539-41.
68. Kublaoui BM, Holder JL Jr, Gemelli T, Zinn AR. SIM1 haploinsufficiency impairs melanocortin-mediated anorexia and activation of paraventricular nucleus neurons. Mol Endocrinol 2006; 20(10): 2483-92.
69. Michaud JL, Boucher F, Melnyk A, et al. SIM1 haploinsufficiency causes hyperphagia, obesity and reduction of the paraventricular nucleus of the hypothalamus. Hum Mol Genet 2001;10:1465-73.
70. Kublaoui BM, Holder JL Jr, Tolson KP, Gemelli T, Zinn AR. SIM1 overexpression partially rescues agouti yellow and dietinduced obesity by normalizing food intake. Endocrinology 2006; 147(10): 4542-9.
71. ALS CNTF Treatment Study Group. A double-blind placebocontrolled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology 1996; 46(5): 1244-9.
72. Lambert PD, Anderson KD, Sleeman MW, et al. Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc Natl Acad Sci USA 2001; 98(8): 4652-7.
73. Kokoeva MV, Yin H, Flier JS. Neurogenesis in the hypothalamus of adult mice: potential role in energy balance. Science 2005; 310(5748): 679-83.
74. Ettinger MP, Littlejohn TW, Schwartz SL, et al. Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study. JAMA 2003; 289(14): 1826-32.
75. Pollack A. Obesity Drug Trial Produces Disappointing Weight Loss (axokine). The New York Times. Published on: April 1, 2003. Available from: http://www.nytimes.com/2003/04/01/business/obesity-drug-trialproduces-disappointing-weight-loss.html. Accessed on September 9, 2011.
76. Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372(9653): 1906-13.
77. Bello NT, Zahner MR. Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity. Curr Opin Investig Drugs 2009; 10(10): 1105-16.
78. Rothman RB, Baumann MH. Serotonergic drugs and valvular heart disease. Expert Opin Drug Saf 2009; 8(3): 317-29.
79. Blaise G, Langleben D, Hubert B. Pulmonary arterial hypertension: pathophysiology and anesthetic approach. Anesthesiology 2003; 99(6): 1415-32.
80. Heisler LK, Cowley MA, Kishi T, et al. Central serotonin and melanocortin pathways regulating energy homeostasis. Ann N Y Acad Sci 2003; 994: 169-74.
81. Smith BM, Smith JM, Tsai JH, et al. Discovery and structureactivity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity. J Med Chem 2008; 51(2): 305-13.
82. Smith SR, Prosser WA, Donahue DJ, Morgan ME, Anderson CM, Shanahan WR. Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women. Obesity (Silver Spring). 2009; 17(3): 494-503.
83. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010; 363(3): 245-56.
84. Fidler MC, Sanchez M, Raether B, et al. One-Year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults: The BLOSSOM Trial. J Clin Endocrinol Metab. J Clin Endocrinol Metab 2011; 96(10): 3067-77.
85. Pollack A. No FDA approval for new diet pill. The New York Times. Published on: October 23, 2010. Available from: http://www.nytimes.com/2010/10/24/business/24obesity.html. Accessed on September 9, 2011.
86. Woolley ML, Bentley JC, Sleight AJ, Marsden CA, Fone KC. A role for 5-HT6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology 2001; 41(2): 210-9.
87. Heal DJ, Smith SL, Fisas A, Codony X, Buschmann H. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol Ther 2008; 117(2): 207-31.
88. Hirst WD, Abrahamsen B, Blaney FE, et al. Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling. Mol Pharmacol 2003; 64(6): 1295-308.
89. Schwartz JC, Arrang JM, Garbarg M, Pollard H, Ruat M. Histaminergic transmission in the mammalian brain. Physiol Rev 1991; 71(1): 1-51.
90. Masaki T, Yoshimatsu H, Chiba S, Watanabe T, Sakata T. Central infusion of histamine reduces fat accumulation and upregulates UCP family in leptin-resistant obese mice. Diabetes 2001; 50(2): 376-84.
91. Sander K, KottkeT, Stark H. Histamine H3 Receptor Antagonists Go to Clinics. Biol Pharm Bull 2008; 31(12):2163-81.
92. ClinicalTrial. gov. Efficacy and Safety Trial to Evaluate the Effect of SCH 497079 on Weight in Obese and Overweight Subjects (Study P05483)(Last Updated on September 30, 2009). Available from: http://clinicaltrials.gov/ct2/show/NCT00642993. Accessed on September 9, 2011.
93. Hancock AA, Bennani YL, Bush EN, et al. Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonist. Eur J Pharmacol 2004; 487(1-3): 183-97.
94. Vermaak I, Hamman JH, Viljoen AM. Hoodia gordonii: an up-todate review of a commercially important anti-obesity plant. Planta Med 2011; 77(11): 1149-60.
95. Bray GA, Greenway FL. Pharmacological treatment of the overweight patient. Pharmacol Rev 2007; 59(2): 151-84.
96. Duenwald M. An Appetite Killer for a Killer Appetite? Not Yet. The New York Times. Published on: April 19, 2005. Available at: http://www.nytimes.com/2005/04/19/health/nutrition/19cons.html. Accessed on September 9, 2011.
97. Oh-I S, Shimizu H, Satoh T, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006; 443(7112): 709-12.
98. Shimizu H, Oh-I S, Okada S, Mori M. Nesfatin-1: an overview and future clinical application. Endocr J 2009; 56(4): 537-43.
99. Inoue K, Valdez GR, Reyes TM, et al. Human urocortin II, a selective agonist for the type 2 corticotropin-releasing factor receptor, decreases feeding and drinking in the rat. J Pharmacol Exp Ther 2003; 305(1): 385-93.
100. Chen P, Vaughan J, Donaldson C, Vale W, Li C. Injection of Urocortin 3 into the ventromedial hypothalamus modulates feeding, blood glucose levels and hypothalamic POMC gene expression but not the HPA axis. Am J Physiol Endocrinol Metab 2010; 298(2): E337-45.
101. Jamieson PM, Cleasby ME, Kuperman Y, et al. Urocortin 3 transgenic mice exhibit a metabolically favourable phenotype resisting obesity and insulin resistance on a high fat diet. Diabetologia 2011; 54(9): 2392-403.
102. Budhiraja S, Chugh A. Neuromedin U: physiology, pharmacology and therapeutic potential. Fundam Clin Pharmacol 2009; 23(2): 149-57.
103. Doggrell SA. Neuromedin U-a new target in obesity. Expert OpinTher Targets 2005; 9(4): 875-7.
104. Egecioglu E, Ploj K, Xu X, et al. Central NMU signaling in body weight and energy balance regulation: evidence from NMUR2 deletion and chronic central NMU treatment in mice. Am J Physiol Endocrinol Metab 2009; 297(3): E708-16.
105. Peier a, Kosinski j, Cox-york k, et al. The antiobesity effects of centrally administered neuromedin u and neuromedin s are mediated predominantly by the neuromedin u receptor 2 (nmur2). Endocrinology 2009; 150(7): 3101-9.
106. Ronnett GV, Kleman AM, Kim EK, Landree LE, Tu Y. Fatty acid metabolism, the central nervous system and feeding. Obesity (Silver Spring) 2006; 14(Suppl 5): 201S-7S.
107. Kuhajda FP, Landree LE, Ronnett GV. The connections between C75 and obesity drug-target pathways. Trends Pharmacol Sci 2005; 26(11): 541-4.
108. Yamada K, Wada E, Santo-Yamada Y, Wada K. Bombesin and its family of peptides: prospects for the treatment of obesity. Eur J Pharmacol 2002; 440(2-3): 281-90.
109. Lieverse RJ, Jansen JB, van de Zwan A, et al. Bombesin reduces food intake in lean man by a cholecystokinin-independent mechanism. J Clin Endocrinol Metab 1993; 76(6): 1495-8.
110. Lieverse RJ, Jansen JB, Masclee AA, Lamers CB. Bombesin reduces food intake after a preload in man by a cholecystokininindependent mechanism. ClinSci (Lond) 1993; 85(3): 277-80.
111. Lieverse RJ, Jansen JB, Masclee AA, Lamers CB. Significant satiety effect of bombesin in lean but not in obese subjects. Int J Obes Relat Metab Disord 1994; 18(8): 579-83.
112. Ohki-Hamazaki H, Watase K, Yamamoto K, et al. Mice lacking bombesin receptor subtype-3 develop metabolic defects and obesity. Nature 1997; 390(6656): 165-9.
113. Guan XM, Chen H, Dobbelaar PH, et al. Regulation of energy homeostasis by bombesin receptor subtype-3: selective receptor agonists for the treatment of obesity. Cell Metab 2010; 11(2): 101-12.
114. Steigerwalt RW, Williams JA. Binding specificity of the mouse cerebral cortex receptor for small cholecystokinin peptides. Regul Pept 1984; 8(1): 51-9.
115. Szewczyk JR, Laudeman C. CCK1R agonists: a promising target for the pharmacological treatment of obesity. Curr Top Med Chem 2003; 3(8): 837-54.
116. Jordan J, Greenway FL, Leiter LA, et al. Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients. Clin Pharmacol Ther 2008; 83(2): 281-7.
117. Crawley JN, Beinfeld MC. Rapid development of tolerance to the behavioral actions of cholecystokinin. Nature 1983; 302(5910): 703-6.
118. Matson CA, Reid DF, Ritter RC. Daily CCK injection enhances reduction of body weight by chronic intracerebroventricular leptin infusion. Am J Physiol Regul Integr Comp Physiol 2002; 282(5): R1368-73.
119. Fernández Landó L, Casellini CM. Exenatide trials for the treatment of type 2 diabetes. Medicina (B Aires) 2009; 69(4): 447-57.
120. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28(5): 1092-100.
121. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28(5): 1083-91.
122. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008; 24(1): 275-86.
123. Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007; 30(6): 1487-93.
124. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372(9645): 1240-50.
125. Parks M, RosebraughC. Weighing risks and benefits of liraglutide-the FDA's review of a new antidiabetic therapy. NEngl J Med 2010; 362(9): 774-7.
126. Neumiller JJ. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc 2009; 49 (Suppl 1): S16-29.
127. Astrup A, Rössner S, Van Gaal L et al. NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374(9701): 1606-16.
128. Neary MT, Batterham RL. Gut hormones: implications for the treatment of obesity. Pharmacol Ther 2009; 124(1): 44-56.
129. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418(6898): 650-4.
130. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349(10): 941-8.
131. Gantz I, Erondu N, Mallick M, et al. Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J Clin Endocrinol Metab 2007; 92(5): 1754-7.
132. Chen SC, Eiting K, Cui K, et al. Therapeutic Utility of a Novel Tight Junction Modulating Peptide for Enhancing Intranasal Drug Delivery. J Pharm Sci 2006; 95(6): 1364-71.
133. Cohen MA, Ellis SM, Le Roux CW, et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 2003; 88(10): 4696-701.
134. Wynne K, Park AJ, Small CJ, et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a doubleblind, randomized, controlled trial. Diabetes 2005; 54(8): 2390-5.
135. Wynne K, Park AJ, Small CJ, et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes (Lond) 2006; 30(12): 1729-36.
136. Bloomgarden ZT. Obesity: mediators and treatment approaches. Diabetes Care 2009; 32(5): e48-52.
137. Mcgavigan ak, Murphy Kg. Gut hormones: the future of obesity treatment? Br j clin pharmacol 2012 mar 27. Doi: 10.1111/j.1365-2125.2012.04278.x.
138. Woods SC, Lutz TA, Geary N, Langhans W. Pancreatic signals controlling food intake; insulin, glucagon and amylin. Philos Trans R Soc Lond B Biol Sci 2006; 361(1471): 1219-35.
139. Butler PC, Chou J, Carter WB, et al. Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. Diabetes 1990; 39(6): 752-6.
140. Lutz ta. Pancreatic amylin as a centrally acting satiating hormone. Curr drug targets 2005; 6(2): 181-9.
141. lutz ta, geary n, szabady mm, del prete e, scharrer e. Amylin decreases meal size in rats. Physiol behav 1995; 58(6): 1197-202.
142. Reidelberger Rd, Haver ac, arnelo u, smith dd, schaffert cs, permert j. Amylin receptor blockade stimulates food intake in rats. Am j physiol regul integr comp physiol 2004; 287(3): r568-7.
143. Ryan G, Briscoe TA, Jobe L. Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes. Drug Des Devel Ther 2009; 2: 203-14.
144. Aronne L, Fujioka K, Aroda V, et al. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, doseescalation study. J Clin Endocrinol Metab 2007; 92(8): 2977-83.
145. Okada S, York DA, Bray GA, Erlanson-AlbertssonC. Enterostatin (Val-Pro-Asp-Pro-Arg), the activation peptide of procolipase, selectively reduces fat intake. Physiol Behav 1991; 49(6): 1185-9.
146. Lin L, Chen J, York DA. Chronic ICV enterostatin preferentially reduced fat intake and lowered body weight. Peptides 1997; 18(5): 657-61.
147. Bowyer RC, Rowston WM, Jehanli AM, Lacey JH, Hermon-Taylor J. Effect of a satiating meal on the concentrations of procolipasepropeptide in the serum and urine of normal and morbidly obese subjects. Gut 1993; 34(11): 1520-5.
148. Prasad C, Imamura M, Debata C, Svec F, Sumar N, Hermon-Taylor J. Hyperenterostatinemia in premenopausal obese women. J Clin Endocrinol Metab 1999; 84(3): 937-41.
149. Rössner S, Barkeling B, Erlanson-Albertsson C, Larsson P, Wåhlin-Boll E. Intravenous enterostatin does not affect single meal food intake in man. Appetite 1995; 24(1): 37-42.
150. Kanatani A, Hata M, Mashiko S, et al. A typical Y1 receptor regulates feeding behaviors: effects of a potent and selective Y1 antagonist, J-115814. Mol Pharmacol 2001; 59(3): 501-5.
151. Antal-Zimanyi I, Bruce MA, Leboulluec KL, et al. Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonist. Eur J Pharmacol 2008; 590(1-3): 224-32.
152. Daniels AJ, Grizzle MK, Wiard RP, Matthews JE, HeyerD. Food intake inhibition and reduction in body weight gain in lean and obese rodents treated with GW438014A, a potent and selective NPY-Y5 receptor antagonist. Regul Pept 2002; 106(1-3): 47-54.
153. Turnbull AV, Ellershaw L, Masters DJ, et al. Selective antagonism of the NPY Y5 receptor does not have a major effect on feeding in rats. Diabetes 2002; 51(8): 2441-9.
154. Kamiji MM, Inui A. Neuropeptide Y receptor selective ligands in the treatment of obesity. Endocr Rev 2007; 28(6): 664-84.
155. Erondu N, Gantz I, Musser B, et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab 2006; 4(4): 275-82.
156. Erickson JC, Clegg KE, Palmiter RD. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 1996; 381(6581): 415-21.
157. Erickson JC, Hollopeter G, Palmiter RD. Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptideY. Science 1996; 274(5293): 1704-7.
158. Ludwig DS, Tritos NA, Mastaitis JW, et al. Melanin-concentrating hormone overexpression in transgenic mice leads to obesity and insulin resistance. J Clin Invest 2001; 107(3): 379-86.
159. Pissios P, Bradley RL, Maratos-Flier E. Expanding the scales: The multiple roles of MCH in regulating energy balance and other biological functions. Endocr Rev 2006; 27(6): 606-20.
160. Marsh DJ, Weingarth DT, Novi DE, et al. Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive, and hyperphagic and have altered metabolism. Proc Natl Acad Sci USA 2002; 99(5): 3240-5.
161. Lin SJ, Ford E, Haigis M, Liszt G, Guarente L. Calorie restriction extends yeast life span by lowering the level of NADH. Genes Dev 2004; 18(1): 12-6.
162. Anderson RM, Shanmuganayagam D, Weindruch R. Caloric restriction and aging: studies in mice and monkeys. Toxicol Pathol 2009; 37(1): 47-51.
163. Heilbronn LK, de Jonge L, Frisard MI, et al. Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: a randomized controlled trial. JAMA 2006; 295(13): 1539-48.
164. Méndez-Andino JL, Wos JA. MCH-R1 antagonists: what is keeping most research programs away from the clinic? Drug Discov Today 2007; 12(21-22): 972-9.
165. Willie JT, Sinton CM, Maratos-Flier E, Yanagisawa M. Abnormal response of melanin-concentrating hormone deficient mice to fast ing: hyperactivity and rapid eye movement sleep suppression. Neuroscience 2008; 156(4): 819-29.
166. Haberman AB. Obesity drug pipeline: developing therapies for a complex disease. Obesity drug pipeline report overview. Insight Pharma reports. (Published in: September 2008). Available at: http://www.insightpharmareports.com/reports_report.aspx?r=653& id=81176. Accessed on: September 9, 2011.
167. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G proteincoupled receptors that regulate feeding behavior. Cell 1998; 92(4): 573-85.
168. Piper DC, Upton N, Smith MI, Hunter AJ. The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats. Eur J Neurosci 2000; 12(2): 726-30.
169. Smart D, Sabido-David C, Brough SJ, et al. SB-334867-A: the first selective orexin-1 receptor antagonist. Br J Pharmacol 2001; 132(6): 1179-82.
170. Haynes AC, Chapman H, Taylor C, et al. Anorectic, thermogenic and anti-obesity activity of a selective orexin-1 receptor antagonist in ob/ob mice. Regul Pept 2002; 104(1-3): 153-9.
171. Kyrkouli SE, Stanley BG, Leibowitz SF. Galanin: stimulation of feeding induced by medial hypothalamic injection of this novel peptide. Eur J Pharmacol 1986; 122(1): 159-60.
172. Corwin RL, Robinson JK, Crawley JN. Galanin antagonists block galanin-induced feeding in the hypothalamus and amygdala of the rat. Eur J Neurosci 1993; 5(11): 1528-33.
173. LeibowitzSF. Differential functions of hypothalamic galanin cell grow in the regulation of eating and body weight. Ann N Y Acad Sci 1998; 863: 206-20.
174. Adams AC, Clapham JC, Wynick D, Speakman JR. Feeding behavior in galanin knockout mice supports a role of galanin in fat intake and preference. J Neuroendocrinol 2008; 20(2): 199-206.
175. Smith BK, York DA, Bray GA. Chronic cerebroventricular galanin does not induce sustained hyperphagia or obesity. Peptides 1994; 15(7): 1267-72.
176. Gundlach AL. Galanin/GALP and galanin receptors: role in central control of feeding, body weight/obesity and reproduction? Eur J Pharmacol 2002; 440(2-3): 255-68.
177. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001; 50(8): 1714-9.
178. Sun Y, Ahmed S, Smith RG. Deletion of ghrelin impairs neither growth nor appetite. Mol Cell Biol 2003; 23(22): 7973-81.
179. Wortley KE, Anderson KD, Garcia K, et al. Genetic deletion of ghrelin does not decrease food intake but influences metabolic fuel preference. Proc Natl Acad Sci USA 2004; 101(21): 8227-32.
180. Wortley KE, del Rincon JP, Murray JD, et al. Absence of ghrelin protects against early-onset obesity. J Clin Invest 2005; 115(12): 3573-8.
181. Asakawa A, Inui A, Kaga T, et al. Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut 2003; 52(7): 947-52.
182. Shuto Y, Shibasaki T, Otagiri A, et al. Hypothalamic growth hormone secretagogue receptor regulates growth hormone secretion, feeding, and adiposity. J Clin Invest 2002; 109(11): 1429-36.
183. Esler WP, Rudolph J, Claus TH, et al. Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss. Endocrinology 2007; 148(11): 5175-85.
184. Salomé N, Hansson C, Taube M, et al. On the central mechanism underlying ghrelin's chronic pro-obesity effects in rats: new insights from studies exploiting a potent ghrelin receptor antagonist. J Neuroendocrinol 2009; 21(9): 777-85.
185. Kopelman P, Bryson A, Hickling R, et al. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes (Lond) 2007; 31(3): 494-9.
186. Kopelman P, Groot Gde H, Rissanen A, et al. Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebocontrolled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). Obesity (Silver Spring) 2010; 18(1): 108-15.
187. Padwal R. Cetilistat, a new lipase inhibitor for the treatment of obesity. Curr Opin Investig Drugs 2008; 9(4): 414-21.
188. Grover GJ, Mellstrom K, Malm J. Development of the thyroid hormone receptor beta-subtype agonist KB-141: a strategy for body weight reduction and lipid lowering with minimal cardiac side effects. Cardiovasc Drug Rev 2005; 23(2): 133-48.
189. Bryzgalova G, Effendic S, Khan A, et al. Anti-obesity, antidiabetic, and lipid lowering effects of the thyroid receptor beta subtype selective agonist KB-141. J Steroid Biochem Mol Biol 2008; 111(3-5): 262-7.
190. Grover GJ, Egan DM, Sleph PG, et al. Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3'-triiodo-Lthyronine. Endocrinology 2004; 145(4): 1656-61.
191. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res 2000; 53(6): 274-8.
192. Valentino MA, Lin JE, Waldman SA. Central and peripheral molecular targets for antiobesity pharmacotherapy. Clin Pharmacol Ther 2010; 87(6): 652-62.
193. Arch JR, Ainsworth AT, Cawthorne MA, et al. Atypical betaadrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature 1984; 309(5964): 163-5.
194. Emorine L, Blin N, Strosberg AD. The human beta 3-adrenoceptor: the search for a physiological function. Trends Pharmacol Sci 1994; 15(1): 3-7.
195. Weyer C, Gautier JF, Danforth E Jr. Development of beta 3-adrenoceptor agonists for the treatment of obesity and diabetes-an update. Diabetes Metab 1999; 25(1): 11-21.
196. Ito M, Grujic D, Abel ED, et al. Mice expressing human but not murine beta3-adrenergic receptors under the control of human gene regulatory elements. Diabetes 1998; 47(9): 1464-71.
197. Connacher AA, Bennet WM, Jung RT. Clinical studies with the beta-adrenoceptor agonist BRL 26830A. Am J Clin Nutr 1992; 55(Suppl1): 258S-261S).
198. Wheeldon NM, McDevitt DG, Lipworth BJ. Cardiac effects of the beta 3-adrenoceptor agonist BRL35135 in man. Br J Clin Pharmacol 1994; 37(4): 363-9.
199. Cypess AM, Lehman S, Williams G, et al. Identification and importance of brown adipose tissue in adult humans. N Engl J Med 2009; 360(15): 1509-17.
200. Weyer C, Tataranni PA, Snitker S, Danforth E Jr, Ravussin E. Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective beta3-adrenoceptor agonist in humans. Diabetes 1998; 47(10): 1555-61.
201. Sum FW, Gilbert A, Venkatesan AM, et al. Prodrugs of CL316243: a selective beta3-adrenergic receptor agonist for treating obesity and diabetes. Bioorg Med Chem Lett 1999; 9(14): 1921-6.
202. Farrigan c, Pang k. Obesity market overview. Nat Rev Drug Discov 2002; 1(4): 257-8.
203. Klingenberg M, Huang SG. Structure and function of the uncoupling protein from brown adipose tissue. Biochim Biophys Acta 1999; 1415(2): 271-96.
204. Boss O, Hagen T, Lowell BB. Uncoupling proteins 2 and 3: potential regulators of mitochondrial energy metabolism. Diabetes 2000; 49(2): 143-56.
205. Argyropoulos G, Brown AM, Willi SM, et al. Effects of mutations in the human uncoupling protein 3 gene on the respiratory quotient and fat oxidation in severe obesity and type 2 diabetes. J Clin Invest 1998; 102(7): 1345-51.
206. Clapham JC, Arch JR, Chapman H, et al. Mice overexpressing human uncoupling protein-3 in skeletal muscle are hyperphagic and lean. Nature 2000; 406(6794): 415-8.
207. Matsuda D, Tomoda H. DGAT inhibitors for obesity. Curr Opin Investig Drugs 2007; 8(10): 836-41.
208. Chen HC, Farese RV Jr. DGAT and triglyceride synthesis: a new target for obesity treatment?. Trends Cardiovasc Med 2000; 10(5): 188-92.
209. Zhao G, Souers AJ, Voorbach M, et al. Validation of diacylglycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor. J Med Chem 2008; 51(3): 380-3.
210. Dobrzyn A, Ntambi JM. Stearoyl-CoA desaturase as a new drug target for obesity treatment. Obes Rev 2005; 6(2): 169-74.
211. Dobrzyn A, Ntambi JM. The role of stearoyl-CoA desaturase in the control of metabolism. Prostaglandins Leukot Essent Fatty Acids 2005; 73(1): 35-41.
212. Tong L. Acetyl-coenzyme A carboxylase: crucial metabolic enzyme and attractive target for drug discovery. Cell Mol Life Sci 2005; 62(16): 1784-803.
213. Shetty S, Kusminski CM, Scherer PE. Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. Trends Pharmacol Sci 2009; 30(5): 234-9.
214. Bredella MA, Torriani M, Ghomi RH, et al. Adiponectin Is Inversely Associated With Intramyocellular and Intrahepatic Lipids in Obese Premenopausal Women. Obesity (Silver Spring) 2011; 19(5): 911-6.
215. Liu YL, Liang HR, Liu HT, et al. Association of serum adiponectin levels with artherosclerosis and the metabolic syndrome in obese children. J Pediatr Endocrinol Metab 2010; 23(8): 743-51.
216. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20(6): 1595-9.
217. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2000; 7(8): 941-6.
218. Yamauchi T, Hara K, Kubota N, et al. Dual roles of adiponectin/Acrp30 in vivo as an anti-diabetic and anti-atherogenic adipokine. Curr Drug Targets Immune Endocr Metabol Disord 2003; 3(4): 243-54.
219. Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001; 98(4): 2005-10.
220. Cheetham SC, Jackson HC, Vickers SP, Dickinson K, Jones RB, Heal DJ. Novel targets for the treatment of obesity: a review of progress. Drug Discovery Today: Therapeutic Strategies 2004; 1(2): 227-35.
221. Bodles AM, Banga A, Rasouli N, Ono F, Kern PA, OwensRJ. Pioglitazone increases secretion of high-molecular-weight adiponectin from adipocytes. Am J Physiol Endocrinol Metab 2006; 291(5): E1100-5.
222. Bensaid M, Gary-Bobo M, Esclangon A, et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003; 63(4): 908-14.
223. Yamada S. Pleiotropic Effects of ARB in Metabolic Syndrome. Curr Vasc Pharmacol 2011; 9(2): 158-61.
224. Sukhija R, Kakar P, Mehta V, Mehta JL. Enhanced 11betahydroxysteroid dehydrogenase activity, the metabolic syndrome, and systemic hypertension. Am J Cardiol 2006; 98(4): 544-8.
225. Morton NM, Seckl JR. 11beta-hydroxysteroid dehydrogenase type 1 and obesity. Front Horm Res 2008; 36: 146-64.
226. Muñoz R, Carvajal C, Escalona A, et al. 11beta-hydroxysteroid dehydrogenase type 1 is overexpressed in subcutaneous adipose tissue of morbidly obese patients. Obes Surg 2009; 19(6): 764-70.
227. Wang SJ, Birtles S, de Schoolmeester J, et al. Inhibition of 11betahydroxysteroid dehydrogenase type 1 reduces food intake and weight gain but maintains energy expenditure in diet-induced obese mice. Diabetologia 2006; 49(6): 1333-7.
228. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994; 79(7): 1147-56.
229. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 1998; 92(6): 829-39.
230. Handschin C, Spiegelman BM. Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev 2006; 27(7): 728-35.
231. Wilson-Fritch L, Nicoloro S, Chouinard M, et al. Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. J Clin Invest 2004; 114(9): 1281-9.
232. Weindruch R, Walford RL, Fligiel S, Guthrie D. The retardation of aging in mice by dietary restriction: longevity, cancer, immunity and lifetime energy intake. J Nutr 1986; 116(4): 641-54.
233. Chaudhary N, Pfluger PT. Metabolic benefits from Sirt1 and Sirt1 activators. Curr Opin Clin Nutr Metab Care 2009; 12(4): 431-7.
234. Elliott PJ, Jirousek M. Sirtuins: novel targets for metabolic disease. Curr Opin Investig Drugs 2008; 9(4): 371-8.
235. Imai s, Armstrong cm, Kaeberlein m, Guarente l. Transcriptional silencing and longevity protein sir2 is an naddependent histone deacetylase. Nature 2000; 403(6771): 795-800.
236. Van Meter M, Mao Z, Gorbunova V, Seluanov A. Repairing split ends: SIRT6, mono-ADP ribosylation and DNA repair. Aging (Albany NY) 2011; 3(9): 829-35.
237. Yamamoto H, Schoonjans K, AuwerxJ. Sirtuin functions in health and disease. Mol Endocrinol 2007; 21(8): 1745-55.
238. Pfluger PT, Herranz D, Velasco-Miguel S, Serrano M, Tschöp MH. Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci USA 2008; 105(28): 9793-8.
239. Yeomans MR, Gray RW. Opioid peptides and control of human ingestivebehaviour. Neurosci Biobehav Rev 2002; 26(6): 713-2.
240. Greenway FL, Fujioka K, Plodkowski RA, et al. COR-I Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010; 376(9741): 595-605.
241. Jones D. Novel pharmacotherapies for obesity poised to enter market. Nat Rev Drug Discov 2009; 8(11): 833-4.
242. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) 2011; 19(1): 110-20.
243. Pollack A. FDA Declines to Approve Diet Drug. The New York Times. Published on: 1 February, 2011. Available from: http://www.nytimes.com/2011/02/02/business/02drug.html Accessed on: February 26, 2012.
244. Gadde KM, Franciscy DM, Wagner HR 2nd, Krishnan KR. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 2003; 289(14): 1820-5.
245. Supuran CT, Di Fiore A, De Simone G. Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs 2008; 13(2): 383-92.
246. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377(9774): 1341-52.
247. Pollack A. FDA Rejects Qnexa, a Third Weight-Loss Drug. The New York Times. Published on: 28 October, 2010. Available from: http://www.nytimes.com/2010/10/29/health/policy/29drug.html. Accessed on: September 9, 2011.
248. Ravussin E, Smith SR, Mitchell JA, et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring) 2009; 17(9): 1736-43.
249. Tam CS, Lecoultre V, Ravussin E. Novel strategy for the use of leptin for obesity therapy. Expert Opin Biol Ther 2011; 11(12): 1677-85.